[Deep venous thrombosis and pulmonary embolism. Prophylaxis and therapy]

Herz. 2005 May;30(3):204-11. doi: 10.1007/s00059-005-2672-y.
[Article in German]

Abstract

Venous thromboembolism is a common cause of morbidity and mortality with an estimated annual incidence of 1:1,000. Several patient groups at risk can be differentiated, according to the presence of endogenous factors (such as hereditary thrombophilic disorders), but much more by exogenous factors (underlying disease). This results in risk-adapted recommendations for prophylaxis and therapy, which will be discussed in the following overview.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Anticoagulants / administration & dosage*
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Pulmonary Embolism / drug therapy*
  • Pulmonary Embolism / prevention & control*
  • Venous Thrombosis / drug therapy*
  • Venous Thrombosis / prevention & control*

Substances

  • Anticoagulants
  • Fibrinolytic Agents